The active metabolite of leflunomide (A771726) has been shown by in vitro studies to be an inhibitor of CYP2C9, which is concerned with the metabolism of tolbutamide. The manufacturers advise caution if leflunomide is given with tolbutamide as increased tolbutamide levels may result. It may be prudent to monitor blood glucose levels on concurrent use.
(15)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.